Antibiotics: From prehistory to the present day

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 3, 2016, Pages 572-575

  Gould, Kate ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; CLAVULANIC ACID; DALBAVANCIN; DAPTOMYCIN; GEMIFLOXACIN; GREPAFLOXACIN; IMIPENEM; LINEZOLID; MEROPENEM; METICILLIN; NALIDIXIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SPARFLOXACIN; SULBACTAM; TAZOBACTAM; TEICOPLANIN; TEMAFLOXACIN; TETRACYCLINE DERIVATIVE; THIENAMYCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG BIOAVAILABILITY; DRUG USE; ENTEROBACTERIACEAE; ENVIRONMENT; GLYCOPEPTIDE RESISTANT ENTEROCOCCI; GRAM NEGATIVE BACTERIUM; HISTORY OF MEDICINE; HUMAN; IN VITRO STUDY; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIUM; PENICILLIUM GLAUCIUM; PSEUDOMONAS; REVIEW; STREPTOMYCES; STREPTOMYCES GRISEUS; ANIMAL; HISTORY;

ANIMALS; ANTI-BACTERIAL AGENTS; HISTORY, 15TH CENTURY; HISTORY, 16TH CENTURY; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS;

EID: 84960804317     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv484     Document Type: Review

References (21)

1. Keyes K, Lee MD, Maurer JJ. Antibiotics: mode of action, mechanisms of resistance and transfer. In: Torrance ME, Isaacson RE, eds. Microbial Food Safety in Animal Agriculture Current Topics. Ames, IA, USA: Iowa State Press, 2003: 45-56.
2. Basset EJ, Keith MS, Armelagos GJ et al. Tetracycline-labeled human bone from ancient Sudanese Nubia (AD 350). Science 1980; 209: 1532-4.
3. Porter R. The Greatest Benefit to Mankind. Waukegan, IL, USA: Fontana Press, 1999.
4. Playfair J. Living with Germs in Health and Disease. Oxford: Oxford University Press, 2004.
5. Levy SB. The Antibiotic Paradox. Cambridge, MA, USA: Perseus Publishing, 2002.
6. Schwartz RS. Paul Ehrlich's Magic Bullets. NEJM 2004; 350: 1079-80.
7. Pruitt RD. William Osler and his Gulstonian Lectures on malignant endocarditis. Mayo Clin Proc 1982; 57: 4-9.
8. Fleming A. On antibacterial action of culture of Penicillium, with special reference to their use in isolation of B. influenzae. Br J Exp Pathol 1929; 10: 226-36.
9. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 2010; 1: 134-45.
10. Shambaugh GE. History of sulphonamides. Arch Otolaryngol 1966; 83: 1-2.
11. Saga T, Yamaguchi K. History of antimicrobial agents and resistant bacteria. Japan Med Assoc J 2009; 52: 103-8.
12. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12.
13. Russell AD. The antibacterial activity of a new cephalosporin, cefamandole. J Antimicrob Chemother 1975; 1: 97-101.
14. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 60-201.
15. Papp-Wallace KM, Edimiani A, Taracila MA et al. Carbapenems: past, present and future. Antimicrob Agents Chemother 2011; 55: 4943-60.
16. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003; 51 Suppl. S1: 13-20.
17. Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother 1988; 21; Suppl A: 1-13.
18. Gould FK. Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 2011; 66 Suppl 4: 3-6.
19. Eisenstein BI, Oleson FB, Balz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 2010; 50 Suppl 1: 10-5.
20. Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc Bayl Univ Med Cent 2006; 19: 155-61.
21. Zhanel CG, Chung P, Zelenitsky S et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014; 74: 31-51.